Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2014. The document serves as a correction to a previous announcement dated October 24, 2014, regarding a transaction by a Person Discharging Managerial Responsibility (PDMR). The correction was necessitated by an administrative error from the Company's external share plan administrator concerning the number of shares actually sold.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a notification of a specific director transaction.
Material Changes and Transaction Details
The filing details a corrected transaction for Mrs. V A Whyte, the Company Secretary:
- Date of Transaction: October 24, 2014
- Option Exercise: 2,250 Ordinary Shares exercised at a price of £11.23 per share (options granted December 2, 2004).
- Share Sale: 2,016 Ordinary Shares sold at a price of £14.08 per share.
- Correction Date: The Company was advised of the revised details on November 13, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a corrected insider trading event.
Key Facts for Investor Verification
- Verify the corrected share sale volume (2,016 shares) against the original October 24, 2014 announcement.
- Confirm the transaction price of £14.08 per share for the sale of Ordinary Shares.
- Note that the filing replaces a prior announcement due to an administrative error by the external share plan administrator.